Impact Biomedicines goes out on a high note

...

Impact Biomedicines recently made headlines in the MPN world and beyond with their push of Fedratinib, which was sold to Celgene who will further develop it for Myelofibrosis. This week they found another way to give back by making their company goodbye party into a fundraiser for MPN Research Foundation and MPN Advocacy and Education, International. Impact Biomedicines leaders Charlie McDermott (President and CBO), John Hood (CEO and one of the inventors of the drug) and Gerrica Clark (Operations Manager) got together to make the event - a concert featuring the Gin Blossoms which took place Monday at iconic rock club Belly Up in San Diego - happen on barely a month's notice. 

Sponsors Medixci, Latham and Watkins and PJT Partners made the event possible and helped to raise collectively over $350,000 for our two organizations! In addition to putting Fedratinib back on the map as a possibility for patients who fail Ruxolitinib, they have made a meaningful contribution to the pursuit of better education, connectivity and research for MPN patients. There is much work to be done, even after the approval of Fedratinib and these funds will go to good use. 

Author: Michelle Woehrle

Michelle Woehrle joined the MPN Research Foundation in 2007 after being inspired by their mission to fund research that will improve the lives of people living with the rare blood cancers PV, ET and MF. In 2015 she was promoted to Executive Director. She has assisted with the expansion of the grants program, grassroots initiatives to connect with more patients internationally and optimize operations for the Foundation.

About the Blog

Check back regularly for updates about what’s happening in the MPN community, from advocacy to research..

x

NEVER MISS AN UPDATE

Get free, timely information on living with an MPN.

Subscribe